Third, the identification of subclinical axillary involvement by AUS may change management recommendations in patients with small triple-negative or HER2-positive breast cancer from primary surgery to PST, with the potential benefit of tailored post-neoadjuvant treatment. The gene discussed is ERBB2; the disease is breast cancer.